The AA. have standardized a method for determining the kaolin activated plasma recalcification time (TRA) and have fixed its normal range between 33 and 60 seconds (average +/- 3 DS) testing 2000 normal subjects. By this method they have been able to demonstrate that TRA is more sensitive than PTT during the haemorrhagic manifestations in thrombocytopenic patients and in monitoring heparin therapy, while it shows a behaviour similar to PTT in detecting coagulation defects. It has also been found that TRA had remarkably increased its values in thrombocytopatic non thrombocytopenic patients, when PTT was normal. TRA does not seem to be useful in coumarin or indanedione therapy, since its values are constantly but not proportionally increased only when prothromsitive than PTT during the haemorrhagic manifestations in thrombocytopenic pabin time is very prolonged. Finally TRA can advantageusly substitute the whole blood clotting time and the non activated recalcification time for its easy performance, remarkable precision and low cost.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ethylenediamine-modified alginate - A hemocompatible platform for polymer-drug conjugates.
Int J Biol Macromol
December 2024
Institute of Chemistry of Komi Scientific Centre of the Ural Branch of the Russian Academy of Sciences, Pervomayskaya st. 48, Syktyvkar 167000, Komi Republic, Russian Federation. Electronic address:
The study is dedicated to the synthesis, rheological properties, hemocompatibility, and further modification of water-soluble derivatives of sodium alginate containing fragments of ethylenediamine (Alg-EDA). Alg-EDA with an equal ratio of amide/amine groups and varying degrees of substitution were synthesized by the carbodiimide method. The influence of the molecular weight of Alg-EDA on the attachment of bioactive molecules such as hydroxybenzoic and ferulic acids was determined.
View Article and Find Full Text PDFKallikrein inhibitor derived from immunoglobulin heavy chain junction region possesses anti-thromboinflammation potential.
Pharmacol Res
November 2024
Engineering Laboratory of Peptides of Chinese Academy of Sciences, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Key Laboratory of Genetic Evolution & Animal Models, Sino-African Joint Research Center, and New Cornerstone Science Laboratory, Kunming Institute of Zoology, the Chinese Academy of Sciences, No.17 Longxin Road, Kunming, Yunnan, 650201, P. R. China. Electronic address:
Article Synopsis
- - Influenza vaccination is linked to lower rates of cardiovascular issues and overall mortality, but the role of related immunoglobulins isn't fully understood.
- - A specific immunoglobulin heavy chain junction sequence (SD6) was found to inhibit plasma kallikrein activity, potentially reducing thromboinflammatory responses and stroke damage.
- - In tests on mice, SD6 decreased thrombosis and cerebral injury without increasing bleeding risk, indicating its promise as a treatment for conditions related to blood inflammation.
Development of substrate-independent heparin coating to mitigate surface-induced thrombogenesis: efficacy and mechanism.
J Mater Chem B
October 2024
College of Polymer Science and Engineering, State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu, 610065, People's Republic of China.
Heparin coatings are widely applied on blood-contact materials to reduce the use of anticoagulants during blood treatment. However, the previous heparin coatings formed covalent binding or electrostatic bonding commonly require complex surface premodification, and the blood coagulation pathway was significantly inhibited to potentially increase the bleeding risk. This contradicts the intended purpose and deviates from the anticoagulation mechanism of the heparin coatings.
View Article and Find Full Text PDFBat-derived oligopeptide LE6 inhibits the contact-kinin pathway and harbors anti-thromboinflammation and stroke potential.
Zool Res
September 2024
Engineering Laboratory of Peptides of Chinese Academy of Sciences, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Key Laboratory of Genetic Evolution & Animal Models, Sino-African Joint Research Center, and New Cornerstone Science Laboratory, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650201, China. E-mail:
Article Synopsis
- Thrombosis and inflammation play key roles in ischemic stroke, and targeting the contact-kinin pathway offers new therapeutic opportunities.
- A bat-derived oligopeptide, LE6, shows promise in stroke therapy by inhibiting important factors involved in clotting (PK and FXIIa) and reducing inflammation.
- LE6 has demonstrated effective anti-thrombotic and anti-inflammatory effects in various animal models, with low toxicity, making it a potential candidate for clinical use in stroke treatment.
Spatiotemporally Controlled Release of Etamsylate from Bioinspired Peptide-Functionalized Nanoparticles Arrests Bleeding Rapidly and Improves Clot Stability in a Rabbit Internal Hemorrhage Model.
ACS Biomater Sci Eng
August 2024
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Kolkata 700054, India.
Achieving rapid clotting and clot stability are important unmet goals of clinical management of noncompressible hemorrhage. This study reports the development of a spatiotemporally controlled release system of an antihemorrhagic drug, etamsylate, in the management of internal hemorrhage. Gly-Arg-Gly-Asp-Ser (GRGDS) peptide-functionalized chitosan nanoparticles, with high affinity to bind with the GPIIa/IIIb receptor of activated platelets, were loaded with the drug etamsylate (etamsylate-loaded GRGDS peptide-functionalized chitosan nanoparticles; EGCSNP).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!